Quick reads

WeFund Health, an international strategic advisory firm focused on market entry strategies, direct investments, and platform-based industry-specific investment vehicles, will support the commercialization of Premier Ocher’s cosmeceuticals brand of Chuda.


Chuda is a treatment cream that effectively hydrates and heals skin. Chuda’s foundation is the Remedea Compound, a proven medicinal remedy used for generations in Georgia (country) to heal the skin. The compound is comprised of 6 indigenous ingredients that grow in mineral rich soil atop the Caucasus mountain range, with Male Pine Flower Pollen, a herbal adaptogen, among them. Apart from visually evident cosmetic anti-aging effects, Chuda has been independently proven to reduce both redness of lesional skin and respective pain. In clinical evaluation conducted by the International Research Services, Chuda decreased skin erythema by 55% in 4 hours vs. 41% reduction in untreated control, a statistically significant improvement. Similar results were received for pain accompanying skin erythema, with 82% pain reduction in Chuda treatment vs. 70% in untreated control.


WeFund Health and Premier Ocher will work together to develop and implement the product commercialization strategy. WeFund Health will leverage its vast network and market insight to identify potential growth opportunities for Chuda and support its expansion in key cosmeceutical markets across Asia, Europe and Russia. The company will utilize its online networking platform to mobilize potential investors and market-access partners.


The $55B cosmeceuticals market is seen by WeFund Health as an attractive investment target. It is projected to grow 9% annually and reach $85B by 2025. This fast growth will be driven by anti-aging injectable products (e.g. solid hyaluronic acid fillers) as well as topical products with proven clinical effectiveness like Chuda. Another trend in the cosmeceuticals market is digital beauty applications that can revolutionize the consumer experience. The investment attractiveness of cosmeceuticals is further strengthened by the availability of numerous small to medium size investment targets actively developing new products. Last year, there were 116 M&A-type transactions in the sector, with activity poised to increase further in 2019 as industry giants enter the fray.

WeFund Health Weekly

Health technology trends, data, innovations
and opportunities - direct to your inbox.